We propose that stem cell advocacy must engage in self-ana lysis to determine how to be maximally effective. For this ana lysis, eight advocacy elements can be measured: agitation, legislation, regulation, litigation, policy development, collaboration, education and innovation. For several of these elements, we show that stem cell advocates, particularly advocates for human embryonic stem cell research, have been matched by their opponents. this demonstrates the need for combining innovation and collaboration with advocacy-oriented education. to pursue innovative and collaborative education, we propose a 'bench-topublic knowledge' model and present some preliminary observations made with this model for different stem cell types. We also propose development of a semantic web information system to be operated within internet cloud/Apps/social Media. We call this system the 'stem cell information technology Accelerator Platform'. toward its construction, we propose formation of a working group to conceive semantic web ontology for stem cell science and its clinical translation into medicine. this ontology would function as a map of the relationships between and among the various informational components comprising discourse on stem cell research and its clinical translation, and would allow various stakeholders to contribute to evolving models of that science and translation. these models could, in turn, support an innovative and collaborative approach to education in furtherance of stem cell advocacy.
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"…Martin Luther King said the tools for advocacy were agitation, legislation, litigation and education. I would add to that, innovation."
-Robert F Kennedy Jr [101, 102] The 'you only get what you can measure' mantra applies broadly in medicine and healthcare, from manufacturing medical products to translating science into medicine. We explore here the hypothesis that this principle applies equally to stem cell advocacy, and we begin by defining the terms 'stem cell' and 'advocacy'.
To define 'stem cell', we incorporate the broad meaning of the term presented by the US NIH: "[c]ells with the ability to divide for indefinite periods in culture and to give rise to specialized cells" [103] . While this definition extends beyond stem cells derived from human embryos (human embryonic stem cells [hESCs] ), the status of hESC research may influence the entire stem cell field. In early 2011, researcher Aaron Levine reported that "[a] survey of US stem cell scientists shows that uncertainty following the legal challenge to the Obama Administration's hESC research policy has negative scientific and economic impacts and affects a range of stem cell scientists, not just those working with hESCs" [1] .
To define 'advocacy', we note that the Latin word 'vocare' ('to call') forms the root of 'advocare' ('to call as witness'). Etymologically, 'stem cell advocacy' thus refers to calling forth the benefits of acquiring knowledge of stem cells and converting that knowledge into medical and other potential technologies [2] .
Hippocrates's oath prohibits new fields of medicine from developing without canonical protection of patient safety [104] . Consequently, we cannot criticize the historic pace at which medicine has been translated from stem cell science. Instead, we seek to explore whether advocates for this science and its translation into medicine have been effective during the past 30-plus years. For this purpose we propose measuring each of the following elements of advocacy: agitation, legislation, regulation, litigation, policy development, collaboration, education and innovation.
Applied to stem cell research, the kinetic energy to which each of these eight forces gives rise must be measured in at least two directions: the first points in favor of such research; the second, in the opposite direction.
To illustrate this bivalence, consider a very serious disease (VSD). Generally, if VSD is chronic in nature or does not threaten pandemic infectious lethality, and patients suffering from VSD do relatively little to advocate developing cures for it, then there is at least some chance, all other things being equal, that a cure for VSD will eventually be found. However, if opponents of technology that may lead to that cure agitate against its use more so than proponents agitate for its use, then the chances of finding that cure will diminish.
But, when the VSD involves the threat of pandemic infectious lethality, a different result can be obtained. In the late 1980s, for example, communities at higher risk for being infected and dying from the sequelae of HIV infection brought their agitation to the US Capitol. Their agitation had traction given the uncertainty as to just how far the causative virus would spread. The urgency in this example, however, does not map into stem cellbased medicine, where, historically (except for a few notable exceptions at the state government level in the USA), there seems to have been more agitation among opponents of stem cell research, particularly hESC research, than among proponents of that research.
The reflection of this historic imbalance can be seen in two sets of opposing legislative and regulatory events.
The first set, in chronological order, comprises:
The September 1980 'Catch 22' decision by the US Department of Health and Human Services making it impossible for the NIH to fund research of in vitro fertilization [3] ;
A 13-year period (1980-1993) during which fetal tissue research in the USA was significantly curtailed due to federal funding policy opposed to such research;
The December 1994 US Presidential directive to the NIH not to allocate federal funds for the 'creation' of human embryos for research purposes;
The signing into law in 1996 of the first Dickey-Wicker Amendment, an annually re-enacted law that prohibits US government funding for creating human embryos for research purposes and research in which human embryos are destroyed, discarded or knowingly subjected to risks greater than that allowed for research on fetuses in utero under the Common Rule (the set of US federal rules for protecting human subjects in research); The second set, in chronological order, comprises:
The 1979 decision of the NIH Ethics Advisory Board that in vitro fertilization is worthy of federally funded study [4] ;
The NIH [107] . In July 2011, after almost 2 years of wrangling on standing and preliminary injunction issues in both the District Court and the Circuit Court of Appeals for the District of Columbia, the District Court ruled in favor of the government's motion for summary judgment, thereby allowing the NIH to proceed funding hESC research under its 2009 Guidelines. As this article went to press, an appeal by plaintiffs was possible but had not been filed.
The aforementioned legislation/ regulation/litigation dialectic suggests that stem cell research policy development, the fifth element of advocacy, has not matured to a steady state at the US federal level. While some innovation in stem cell advocacy stem cell research policy has borne fruit in some states (most notably, the states comprising the Interstate Alliance for Stem Cell Research [108] 
We note here that the collaborations among stem cell researchers and clinicians around the world, mediated in significant part through the efforts of CIRM, has offered a model for broad geographic collaboration among stem cell advocates [109], but we nonetheless believe in the necessity for the NIH to take a sustained and leading role.
The globally oriented collaborative approach that has evolved for stem cell science should also be pursued for stem cell advocacy. The Stem Cell Action Coalition, initiated by Genetics Policy Institute in November 2010, exemplifies this pursuit. The Coalition seeks to serve "as an engine uniting the procures community" by maintaining a continually curated website, hosting periodic conference calls among the advocacy groups comprising the Stem Cell Action community, and preparing and disseminating periodic newsletters [110] . The annual World Stem Cell Summit, produced and co-organized by the Genetics Policy Institute, provides another example of collaboration among stem cell advocates. The Summit "brings together scientists, patients, advocates, business people, investors, educators, ethicists, policy makers and government representatives from around the world" [111] . The Alliance for Regenerative Medicine offers a third example of the collaborative approach to advocacy. The Alliance for Regenerative Medicine focuses on "legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine" [112] . Alliance for Regenerative Medicine's members include over 80 organizations, including companies, research organizations, investors, and patient advocacy groups.
Turning to education, we propose a simplified bench-to-public knowledge model consisting of three reservoirs of scientific and medical knowledge (Figure   1 
Scientific experiments and clinical studies Scientific publications relating to those experiments, studies and their results
Publications in the lay media relating to the first two reservoirs As a proxy for the first reservoir, we use annual NIH research awards (a proxy for clinical studies would be the ClinicalTrials.gov database); for the second reservoir, the annual number of publications listed in the PubMed database maintained by the US National Library of Medicine (this second reservoir could be expanded to include online patent databases and disclosure documents mandated by securities laws); and for the third reservoir, an online database of news articles. We have applied this model to four fields within stem cell science and a control field: stem cells in general; hESCs; adult stem cells; induced pluripotent stem (iPS) cells; and, as the control, nanobased medical technology (Table 1) . Presentation and ana lysis of the data from this exercise extends beyond this paper, but we offer some very general observations:
iPS cells seem to be growing into a position of dominance at the experimental level, leading to a rapid increase in the annual number of iPSC scientific papers and related reports in the lay media; The number of reports in the lay media in the USA regarding 'stem cells, in general' has fallen from its peak in 2005, but may be experiencing an upswing driven by reports on iPSCs;
Except for some volatility in the lay media in the early 1990s, experiments, scientific reports and lay reports for nano-based medical technology do not present as much volatility as do stem cell-based fields.
Optimizing the information flow from the laboratory to public media through innovative collaboration and education can play a key role in stem cell advocacy. Toward this vision we propose development of the Stem Cell Information Technology Platform -a linked database, semantic web, ontologically driven information system that uses the various dissemination tools within the Internet Cloud/Apps/Social Media. The Stem Cell Information Technology Platform ontology could serve as a map of the relationships among the components of information on stem cell science and its clinical translation into medicine. This ontology would enable all interested stakeholders to contribute to models of stem cell science and its clinical translation, and would, in turn, support progress in the other elements of stem cell advocacy discussed above. We propose the formation of a working group to focus on constructing this ontology.
The next 5-10 years of stem cell advocacy may turn, in significant part, on the ability to implement innovative, collaborative tools to educate all stakeholders about the benefits and costs of stem cell science and its translation into medicine. We envision two such tools here: a preliminary model of the 'benchto-public knowledge' process; and a No writing assistance was utilized in the production of this manuscript. [6] .
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Asc: Adult stem cell; hesc: Human embryonic stem cell; iPsc: induced pluripotent stem cell; Nano: Nanomedicine; PM: PubMed; sc: stem cell. 
